2023
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
McHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.Peer-Reviewed Original ResearchMeSH KeywordsCystadenocarcinoma, SerousCystadenoma, SerousFemaleHumansMutationNeoplasm Recurrence, LocalOvarian NeoplasmsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ConceptsOvarian serous borderline tumorsSerous borderline tumorsNon-invasive implantsDisease-free survivalKRAS mutationsTumor recurrenceExtraovarian implantsAdverse disease-free survivalWorse disease-free survivalHigher stage diseaseKRAS mutation testingHigher tumor stageWild-type KRASBRAF V600E mutationBRAF mutational analysisBorderline tumorsClinical outcomesHistological subtypesTumor stageBRAF mutationsUseful biomarkerInvasive implantsTumors correlatesV600E mutationMutational status
2017
KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome
Zuo T, Wong S, Buza N, Hui P. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. Modern Pathology 2017, 31: 350-357. PMID: 29027536, DOI: 10.1038/modpathol.2017.121.Peer-Reviewed Original ResearchConceptsAtypical proliferative serous tumorNon-invasive implantsDisease-specific survivalSerous borderline tumorsHigh recurrence rateWorse disease-specific survivalStage IIIC diseaseKRAS mutationsInvasive implantsBRAF V600E mutationBorderline tumorsSerous tumorsRecurrence rateIIIC diseaseClinical outcomesHistological subtypesPrognostic indicatorExtraovarian implantsV600E mutationLow-grade serous carcinomaUnfavorable disease-specific survivalAdverse clinical outcomesHigher stage diseaseSignificant prognostic indicatorBRAF mutation frequencyPathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerPediatric papillary thyroid cancerPrognostic implicationsPediatric papillary thyroid carcinomaNegative casesBRAF-negative casesBRAF-negative patientsBRAF-positive casesTertiary medical centerAggressive clinical coursePapillary thyroid carcinomaSurgical pathology diagnosisCommon genetic aberrationsNegative patientsAggressive courseClinical coursePathologic characteristicsCase seriesClinical outcomesRetrospective reviewAggressive featuresPediatric casesRecurrence rateRetrospective studySingle institution
2013
Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with BRAFV600E Mutational Analysis
Bernstein J, Virk RK, Hui P, Prasad A, Westra WH, Tallini G, Adeniran AJ, Udelsman R, Sasaki CT, Roman SA, Sosa JA, Prasad ML. Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with BRAFV600E Mutational Analysis. Thyroid 2013, 23: 1525-1531. PMID: 23682579, DOI: 10.1089/thy.2013.0154.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, PapillaryDNA Mutational AnalysisFemaleHumansLymphatic MetastasisMaleMiddle AgedMutationPrognosisProto-Oncogene Proteins B-rafThyroid NeoplasmsConceptsTall cell variantPapillary thyroid microcarcinomaPapillary microcarcinomaCell variantLymphovascular invasionNode metastasisThyroid microcarcinomaAdvanced stageCentral compartment lymph node metastasisLateral cervical node metastasesStage III/IVACentral compartment lymph nodesLateral cervical nodesMultifocal papillary carcinomaLymph node dissectionCervical node metastasisLymph node metastasisPapillary thyroid carcinomaNode dissectionTotal thyroidectomyCervical nodesLymph nodesClinicopathologic featuresMultifocal tumorsAggressive features
2012
BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation
Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML. BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation. Modern Pathology 2012, 26: 62-70. PMID: 22918165, DOI: 10.1038/modpathol.2012.152.Peer-Reviewed Original ResearchConceptsPapillary thyroid microcarcinomaThyroid microcarcinomaPapillary thyroid carcinomaFollicular variantThyroid carcinomaLateral cervical node metastasesOsteoclastic-type giant cellsCervical node metastasisInfiltrative tumor borderGroup of tumorsBRAF V600E mutationClassic nuclear featuresGenotype-phenotype correlationStromal calcificationLymphovascular invasionNode metastasisClinicopathologic featuresLymphocytic infiltrationAggressive featuresTumor sizeCystic changesPapillary microcarcinomaAbsence of mutationsHigh prevalenceMicrocarcinomaBRAF mutation testing in clinical practice
Ziai J, Hui P. BRAF mutation testing in clinical practice. Expert Review Of Molecular Diagnostics 2012, 12: 127-138. PMID: 22369373, DOI: 10.1586/erm.12.1.Peer-Reviewed Original ResearchMeSH KeywordsDNA Mutational AnalysisHumansMAP Kinase Signaling SystemMolecular Targeted TherapyMutation, MissenseNeoplasmsProtein Structure, TertiaryProto-Oncogene Proteins B-rafConceptsHairy cell leukemiaBRAF mutation testingPapillary thyroid carcinomaMalignant melanomaThyroid carcinomaCell leukemiaClinical practiceCutaneous malignant melanomaSerine/threonine-protein kinase BRAFCurrent clinical practiceImportant biological markerMEK/ERKTreatment paradigmClinical trialsHigh prevalenceBRAF inhibitorsBRAF mutationsMutation testingPrecision cancer therapyTherapeutic guidanceMutant BRAFLethal diseaseBiological markersCancerHuman cancersPapillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct
Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chhieng DC, Carling T, Roman SA, Sosa JA, Udelsman R, Theoharis CG, Prasad ML. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 2012, 60: 1052-1059. PMID: 22335197, DOI: 10.1111/j.1365-2559.2011.04149.x.Peer-Reviewed Original Research
2011
BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance
Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C. BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance. Acta Cytologica 2011, 55: 570-575. PMID: 22156468, DOI: 10.1159/000333274.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiopsy, Fine-NeedleCarcinomaCarcinoma, PapillaryCell Transformation, NeoplasticDNA Mutational AnalysisFemaleHumansMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrognosisProto-Oncogene Proteins B-rafRiskTerminology as TopicThyroid Cancer, PapillaryThyroid GlandThyroid NeoplasmsThyroid NoduleConceptsPapillary thyroid carcinomaBRAF mutation analysisBRAF mutationsUndetermined significanceFollicular lesionsUndetermined significance/follicular lesionFine needle aspiration cytology specimensAUS/FLUS categoryMutation analysisBRAF-positive casesIndeterminate thyroid FNAsAspiration cytology specimensRisk of malignancySurgical pathology outcomeFine-needle aspiration specimensBRAF mutation testingNegative predictive valueSurgical pathology reportsThyroid follicular lesionsPredictability of malignancyThyroid fine-needle aspiration specimensSurgical interventionFinal diagnosisPathology outcomesPathology reportsReflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study
Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC. Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study. Thyroid 2011, 21: 717-723. PMID: 21568726, DOI: 10.1089/thy.2011.0021.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorBiopsy, Fine-NeedleCarcinomaCarcinoma, PapillaryChildDNA Mutational AnalysisFemaleHumansMaleMiddle AgedPoint MutationPolymorphism, Single-Stranded ConformationalProspective StudiesProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid GlandThyroid Neoplasms
2005
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 6373-6379. PMID: 16174717, DOI: 10.1210/jc.2005-0987.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, PapillaryFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins B-rafThyroid NeoplasmsConceptsPapillary thyroid cancerBRAF mutation statusBRAF mutationsClinicopathological predictorsRisk stratificationClinicopathological outcomesThyroid cancerPTC subtypesMutation statusTumor stage III/IVStage I/II diseaseMultivariate analysisTumor BRAF mutation statusStage III/IVInitial tumor characteristicsLymph node metastasisPoor clinicopathological outcomesInitial surgeryRecurrent diseaseClinical courseIndependent predictorsNode metastasisClinicopathological characteristicsSubsequent recurrenceTreatment failure